ADA and Immunodeficiency: An adenosine deaminase-severe combined immune deficiencies (ADA-SCID) trial was conducted in the EU by Bordignon C. et al., and those results indicated successful gene transfer in long-lasting progenitor cells, the immune repertoire of the patients was normalized, and their humoral immunities were restored after two years of treatment [6].